Evercore ISI initiated coverage of Benitec Biopharma with an Outperform rating and $25 price target. BB-301 represents \"an exciting opportunity in the rare disease space,\" particularly for treating oculopharyngeal muscular dystrophy, where there are no current therapies, the analyst tells investors. The company has \"significant commercial potential, with estimates suggesting a market of over $1B,\" the analyst added.
